person · Reporting owner

EDWARDS JEFFREY L

Disclosed activity across 4 companies

Tapewire entity: 37453
SEC CIK: 0001190642

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247	Director	April 21, 2026	April 23, 2026
Clearside Biomedical, Inc.CLSD · Entity 82875	Director	June 20, 2024	June 21, 2024
KYNTRA BIO, INC.KYNB · Entity 7431	Director	June 12, 2026	June 17, 2026
LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447	Director	July 08, 2024	July 10, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-RAD LABORATORIES, INC.

Report date April 21, 2026 · Filed April 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	715	Reported balance After 2026-04-21 transaction · row 1 1 source row Row 1 · 2026-04-21 · Exercise / conversion · Acquired 407 · Balance 715 F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	369	Reported balance After 2026-04-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-21 · Grant · Acquired 369 · Balance 369 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-04-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-21 · Exercise / conversion · Disposed 407 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Class A common stock acquired on the vesting of restricted stock units.

F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F3: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Clearside Biomedical, Inc.

Report date June 20, 2024 · Filed June 21, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-06-19	Direct	45,000	Reported balance After 2024-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.

KYNTRA BIO, INC.

Report date June 12, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2036-06-11	Direct	7,000	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

LIFECORE BIOMEDICAL, INC. \DE\

Report date July 08, 2024 · Filed July 10, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	79,667	Reported balance After 2024-07-08 transaction · row 1 1 source row Row 1 · 2024-07-08 · Grant · Acquired 30,000 · Balance 79,667 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 12, 2026 Filed Jun 17, 2026 23:42 UTC	KYNTRA BIO, INC. KYNB · Entity 7431	GrantStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $7.13	$0.00	Disclosure SEC source: 0001190642-26-000004 · form4-06172026_110619.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant. Read SEC document
April 21, 2026 Filed Apr 23, 2026 19:24 UTC	BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	407	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001190642-26-000002 · wk-form4_1776972296.xml · derivative · entry 3 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document
April 21, 2026 Filed Apr 23, 2026 19:24 UTC	BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247	GrantRestricted Stock Units · Derivative	369	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001190642-26-000002 · wk-form4_1776972296.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369 Underlying: Bio-Rad A Common Stock · 369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document
April 21, 2026 Filed Apr 23, 2026 19:24 UTC	BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247	Exercise / conversionBio-Rad A Common Stock	407	$0.00	$0.00	Disclosure SEC source: 0001190642-26-000002 · wk-form4_1776972296.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:20 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	120,000	$0.00 Strike: $0.31	$0.00	Disclosure SEC source: 0001415889-25-015987 · form4-06062025_080655.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of four equal quarterly installments measured from the date of grant or the date of the next annual meeting of stockholders, subject to the reporting person's continued service at each applicable vest date. Read SEC document
April 22, 2025 Filed Apr 24, 2025 21:13 UTC	BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	308	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-25-007905 · form4.xml · derivative · entry 3 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 6, 2024, the reporting person was granted 308 restricted stock units, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the Company's next annual stockholder meeting following the grant date. F4 · derivative.expiration_date: On September 6, 2024, the reporting person was granted 308 restricted stock units, vesting at 100% on the earlier of the first anniversary of the grant date or the date of the Company's next annual stockholder meeting following the grant date. Read SEC document
April 22, 2025 Filed Apr 24, 2025 21:13 UTC	BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247	GrantRestricted Stock Units · Derivative	407	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-25-007905 · form4.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407 Underlying: Bio-Rad A Common Stock · 407 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F3 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document
April 22, 2025 Filed Apr 24, 2025 21:13 UTC	BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247	Exercise / conversionBio-Rad A Common Stock	308	$0.00	$0.00	Disclosure SEC source: 0001062993-25-007905 · form4.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
September 06, 2024 Filed Sep 10, 2024 17:52 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	GrantRestricted Stock Units · Derivative	308	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-24-016370 · form4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308 Underlying: Bio-Rad A Common Stock · 308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders. Read SEC document
July 08, 2024 Filed Jul 10, 2024 23:46 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-031630 · wk-form4_1720655169.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,667 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration. Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:15 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	45,000	$0.00 Strike: $1.15	$0.00	Disclosure SEC source: 0001415889-24-017823 · form4-06212024_040611.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document
June 05, 2024 Filed Jun 7, 2024 00:00 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $1.21	$0.00	Disclosure SEC source: 0001415889-24-015856 · form4-06062024_080610.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
February 01, 2024 Filed Feb 2, 2024 23:35 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	9,554	$0.00	$0.00	Disclosure SEC source: 0001628280-24-003134 · wk-form4_1706916917.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024. Read SEC document
February 01, 2024 Filed Feb 2, 2024 23:35 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionCommon Stock	9,554	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-003134 · wk-form4_1706916917.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:39 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $1.31	$0.00	Disclosure SEC source: 0001209191-23-039422 · doc4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2024, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document
June 09, 2023 Filed Jun 9, 2023 23:53 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	SaleCommon Stock	4,624	$17.51	$80,966.24	Disclosure SEC source: 0001209191-23-036076 · doc4.xml · nonDerivative · entry 3 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,977 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.16 to $17.72. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 09, 2023 Filed Jun 9, 2023 23:53 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	SaleCommon Stock	3,265	$16.74	$54,656.10	Disclosure SEC source: 0001209191-23-036076 · doc4.xml · nonDerivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,601 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F3 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.15 to $17.13. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:53 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	12,666	$0.00 Strike: $17.13	$0.00	Disclosure SEC source: 0001209191-23-036076 · doc4.xml · derivative · entry 4 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,666 Underlying: Common Stock · 12,666 shares Expires 2033-06-06 F5 · derivative.exercise_date: Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:53 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	8,289	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036076 · doc4.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,866 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 19:16 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantCommon Stock	18,182	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-020831 · wk-form4_1685992567.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,113 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date). Read SEC document
May 31, 2023 Filed Jun 1, 2023 23:02 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	9,474	$0.00	$0.00	Disclosure SEC source: 0001628280-23-020580 · wk-form4_1685660536.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.exercise_date: The restricted stock units vested on May 31, 2023. F2 · derivative.expiration_date: The restricted stock units vested on May 31, 2023. Read SEC document
May 31, 2023 Filed Jun 1, 2023 23:02 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	Exercise / conversionCommon Stock	9,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-020580 · wk-form4_1685660536.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: The restricted stock units vested on May 31, 2023. Read SEC document
February 01, 2023 Filed Feb 2, 2023 22:31 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447	GrantRestricted Stock Unit · Derivative	9,554	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-002100 · wf-form4_167537706495984.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,554 Underlying: Common Stock · 9,554 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:23 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $1.62	$0.00	Disclosure SEC source: 0001209191-22-039227 · doc4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2023. Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:10 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	25,684	$0.00 Strike: $9.00	$0.00	Disclosure SEC source: 0001209191-22-038609 · doc4.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,684 Underlying: Common Stock · 25,684 shares Expires 2032-06-15 F2 · derivative.exercise_date: Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:10 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	15,777	$0.00	$0.00	Disclosure SEC source: 0001209191-22-038609 · doc4.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,577 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:16 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016486 · wf-form4_165463659905287.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,059 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 4, 2021. F3 · derivative.exercise_date: The restricted stock units vested on June 4, 2022. F3 · derivative.expiration_date: The restricted stock units vested on June 4, 2022. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:16 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016486 · wf-form4_165463659905287.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,457 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:46 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	9,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-016010 · wf-form4_165418837484136.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Stock · 9,474 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
October 14, 2021 Filed Oct 18, 2021 16:23 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	5,398	$9.77	$52,738.46	Disclosure SEC source: 0001593968-21-002278 · primary_01.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,398 shares Expires 2021-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on October 14, 2020. F3 · derivative.exercise_date: The restricted stock units vested on October 14, 2021. F3 · derivative.expiration_date: The restricted stock units vested on October 14, 2021. Read SEC document
October 14, 2021 Filed Oct 18, 2021 16:23 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	5,398	$9.77	$52,738.46	Disclosure SEC source: 0001593968-21-002278 · primary_01.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,398 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
June 10, 2021 Filed Jun 11, 2021 21:37 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $3.11	$0.00	Disclosure SEC source: 0001209191-21-039955 · doc4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 10, 2022. Read SEC document
June 04, 2021 Filed Jun 8, 2021 23:51 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	7,059	Not disclosed	Not disclosed	Disclosure SEC source: 0001593968-21-001565 · primary_01.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059 Underlying: Common Stock · 7,059 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
May 26, 2021 Filed May 28, 2021 23:04 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $20.86	$0.00	Disclosure SEC source: 0001209191-21-036675 · doc4.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-05-25 F2 · derivative.exercise_date: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
May 26, 2021 Filed May 28, 2021 23:04 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	4,700	$0.00	$0.00	Disclosure SEC source: 0001209191-21-036675 · doc4.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
October 14, 2020 Filed Oct 16, 2020 21:19 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	5,398	Not disclosed	Not disclosed	Disclosure SEC source: 0001593968-20-002056 · primary_01.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,398 Underlying: Common Stock · 5,398 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
June 18, 2020 Filed Jun 19, 2020 20:38 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $2.00	$0.00	Disclosure SEC source: 0001209191-20-037950 · doc4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 18, 2021. Read SEC document
June 04, 2020 Filed Jun 9, 2020 00:25 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $32.69	$0.00	Disclosure SEC source: 0001209191-20-035147 · doc4.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2030-06-03 F2 · derivative.exercise_date: Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 04, 2020 Filed Jun 9, 2020 00:25 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	4,700	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035147 · doc4.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:23 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $1.07	$0.00	Disclosure SEC source: 0001209191-19-038767 · doc4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2020. Read SEC document
June 05, 2019 Filed Jun 7, 2019 22:52 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $39.03	$0.00	Disclosure SEC source: 0001209191-19-035650 · doc4.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document
June 05, 2019 Filed Jun 7, 2019 22:52 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	4,700	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035650 · doc4.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document
September 26, 2018 Filed Sep 28, 2018 20:23 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	GrantStock Option (right to buy) · Derivative	22,500	$0.00 Strike: $6.03	$0.00	Disclosure SEC source: 0001209191-18-052558 · doc4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2028-09-25 F1 · derivative.exercise_date: This option will vest and become exercisable in 36 equal monthly installments through September 26, 2021, subject to the reporting person's continuous service as of such vesting dates. Read SEC document
June 05, 2018 Filed Jun 7, 2018 23:26 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $55.30	$0.00	Disclosure SEC source: 0001209191-18-036509 · doc4.xml · derivative · entry 2 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document
June 05, 2018 Filed Jun 7, 2018 23:26 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	3,700	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036509 · doc4.xml · nonDerivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document
June 07, 2017 Filed Jun 9, 2017 22:36 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $28.65	$0.00	Disclosure SEC source: 0001209191-17-038997 · doc4.xml · derivative · entry 1 EDWARDS JEFFREY L · CIK 0001190642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.